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We investigated the . ability of the purified recombinant 
human cytokines: tumor necrosis factor-alpha (rTNF), gran-
ulocyte-macrophage colony-stimulating factor (rGM-CSF), 
interleukin-1 beta (riL-1), interleukin-3, and tumor necrosis 
factor-beta (rTNF-beta) to stimulate neutrophil adherence 
(NA) to basement membranes (BMs) of stratified squamous 
epithelia pretreated with autoantibodies (ABM) specific for 
the BM matrix protein, type-VII collagen. rTNF, rG M -CSF, 
riL-1, and rTNF-beta, but not IL-3, stimulated NA and stim-
ulation was ABM- and cytokine-concentration-dependent. 
Stimulation was cytokine-specific and not due to endotoxin 
since it was significantly in~ibited by cytokine-specific anti-
bodies but not by polymyxm B (PB). rTNF and rGM-CSF 
T here is accumulating evidence that cytokines may play a role in autoantibody and immune-complex-me-diated inflammation. Studies have shown that: im-mune complexes can stimulate the production of IL-l, TNF, and other cytokines by n1.ononuclear cells, 
either directly by Fc-dependent mechanisms or indirectly by acti-
vating the complement system and ~enerating soluble and insol~ble 
complement intermediates [1-~]; rmmune complexes can pnme 
animals for TNF productron 111 ~1vo [5]; ~L-1 and TNF ~ene expres-
sion and TNF protein production are mcreased m kidneys from 
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Abbreviations: 
ABM: antibasement membrane antibody 
BM: basement membrane 
EBA: epidermolysis bullosa acquisita 
GM-CSF: granulocyte-macrophage colony-stimulating factor 
H&E: hematoxylin and eosin 
IL-1 : interleukin-1 beta 
IL-3: interleukin-3 
NA: neutrophil adherence 
NHS: normal human serum 
PB: polymyxin B 
PBS: phosphate-buffered saline 
TNF: tumor necrosis factor-alpha 
TNF-beta: tumor necrosis factor-beta 
were the most potent stimulators, were effective at concen-
trations < 0.067 ng/ml, and stimulated NA > 600%. Rela-
tive potency was: rTNF = rGM-CSF > rTNF-beta > riL-
l. Stimulation by rTNF was due to a rapid, time-dependent 
effect on the neutrophil, and NA appeared to be dependent, 
in part, on the low-affinity neutrophil receptor for IgG, 
Fc(gamma)RIII, because it could be specifically inhibited by 
monoclonal antibody (3G8) to Fc(gamma)RIII. These results 
suggest that rTNF, rGM-CSF, riL-1, and rTNF-beta may 
contribute individually or in combination to immune-me-
diated inflammation and tissue injury by stimulating immune 
adherence of neutrophils to tissue-bound autoantibodies and 
immune complexes.] Invest Dermatol 95:164-171, 1990 
animals with spontaneous and experimental autoimmune and im-
mune-complex-mediated glomerulonephritis [6-8); IL-1, TNF, 
TNF-beta (formerly known as lymphotoxin), and various CSF and 
chemotactic lymphokines are present in inflammatory lesions in 
human diseases (rheumatoid arthritis, bullous pemphigoid) sus-
pected of having an autoantibody or immune-complex pathogen-
esis (9- 13 J; and administration of IL-1 can accelerate the onset and 
severity of synovitis in an experimental animal model of immune-
mediated arthritis [14]. 
Cytokines could contribute to autoantibody and immune-com-
plex-mediated inflammation by effects that are independent of leu-
kocyte interactions with autoantibodies and immune complexes. A 
number of antibody-independent effects of IL-1, TNF, GM-CSF, 
and TNF-beta have been demonstrated, including: activating vascu-
lar endothelial cells [ 15- 17]; stimulating the production ofbiologi-
cal response modifiers [ 18- 24]; priming leukocyte responses to bio-
logical response modifiers [25- 29]; and directly stimulating a 
variety of leukocyte functions [25,26,28,30- 38]. They could also 
contribute by effects that are dependent on leukocyte interactions 
with antibodies. For example, TNF, GM-CSF, and TNF-beta can 
stimulate neutrophil-mediated and antibody-dependent: cytotoxic-
ity [38-40], substrate proteolysis [40], production of reactive oxy-
gen metabolities (30], and phagocytosis (40-42] . Those effects sug-
gest cytokines may contribute to tissue injury by stimulating 
functions of neutrophils adherent to autoantibody-coated cells and 
connective tissues, or tissue-deposited immune complexes. 
Although TNF, GM-CSF, and TNF-beta can stimulate functions 
of neutrophils adherent to antibody-coated surfaces, it is unclear to 
what extent they can stimulate adherence of neutrophils to those 
surfaces. By stimulating immune adherence, cytokines could pro-
mote localization and Fc-dependent activation of neutrophils at 
sites of antibody deposition and either enhance the effects of other 
biological response modifiers, or perhaps function independently to 
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initiate antibody-dependent inflammation. Because of the potential 
importance of immune adherence in autoantibody and immune-
complex-mediated inflammation, we investigated the ability of se-
lected cytokines to stimulate the adherence of neutrophils to tissue-
bound ABM. 
MATERIALS AND METHODS 
Purified Recombinant Human Cytokines Stock solutions of 
human rTNF (10 ,ug/ml), riL-1 beta (10 ng/ml), riL-3 (5 ng/ml), 
and rGM-CSF (100 ng/ml) were obtained from Genzyme Corp. 
(Boston, MA). Human rTNF-beta, 100 ,ug/ml, was kindly pro-
vided by Genentech Corp. (San Francisco, CA). All cytokines were 
aliquoted and stored frozen at - 80 o C. 
Cytokine and Receptor Antisera Rabbit antisera to purified 
human rTNF and IgG fractions (1 mg/ml) of rabbit antisera to 
purified human riL-l beta and rGM-CSF were obtained from Gen-
zyme Corp. Antiserum to rTNF contained 5- 10 X 106 neutraliz-
ing U/ml. IgG fractions of rabbit antisera to purified riL-l and 
rGM-CSF each contained 1,000 U of neutralizing activity/mi. 
Rabbit antisera to purified rTNF-beta (1 X 106 U of neutralizing 
activity/ml) was prepared by immunizing rabbits with rTNF-beta. 
The antiserum showed no neutralizing activity for rTNF. Antisera 
and IgG fractions were aliquoted and stored in 0.01 M sodium 
phosphate buffer, pH 7.2 (PBS) at 4 and -80°C, respectively. 
Monoclonal Antibodies Mouse monoclonal antibody, 3G8, to 
neutrophil Fc(gamma)RIII was purified from mouse ascites fluid 
(kindly provided by Dr. Jay Unkeless, Rockefeller University) by 
precipitation with caprylic acid and ammonium sulfate as pre-
viously described [43]. The specificity and blocking activity of the 
antibody have previously been characterized (44]. Mouse monoclo-
nal antibodies, HB95, and HB120, to HLA framework antigens 
expressed on human neutrophil were the kind gift of Dr. Jeffrey 
Frelinger (University of North Carolina). All antibodies were ali-
quoted and stored frozen in PBS at - 80 o C. 
Human Skin and Sera Neonatal human foreskin was obtained 
immediately following elective circumcision as approved by our 
Human Rights Committee, washed twice in RPM! (endotoxin 
level of< 10 pg/ml), cut into 5 X 5 mm pieces, quick frozen in 
liquid N 2 , mounted in OCT compound (Miles Scientific, Naper-
ville, IL) and stored frozen at- 80 o C until used. Sera were obtained 
from 6 patients with epidermolysis bullosa acquisita (EBA). Three 
of the sera contained IgG ABM specific for type-VII collagen at 
titers of 1:40-1:80 by indirect immunofluorescence. They were 
negative for IgA, IgM, and IgE ABM by indirect immunofluores-
cent analysis . Specificity for type-VII collagen was confirmed by 
Western immunoblots as previously described [45 ,46]. Three addi-
tional EBA sera were negative for ABM by indirect immunofluores-
cence. Normal human serum (NHS) was obtained from normal 
volunteers. Aliquots ofEBA seta and NHS were heat-inactivated at 
56 oc for 30 min, aliquoted, and stored frozen at - 80°C. IgG frac-
tions were prepared from one of the ABM-positive EBA sera and 
one NHS by ammonium sulfate precipitation and staphylococcal 
protein-A affinity chromatography. All sera and IgG fractions had 
undetectable levels of endotoxin as measured using a limulus ame-
bocyte lysate assay (Endotect, ICN Biomedicals Inc., Cleveland, 
OH) capable of detecting 60.0 pg/ml. 
Normal Human Neutrophils Normal human neutrophils were 
purified under sterile conditions from freshly drawn human blood 
anticoagulated with 40 U j ml preservative-free porcine heparin 
(Sigma Chemical Co., St. Louis, MO). Five milliliters of heparin-
ized blood were layered over 4 ml of Hypaque-Ficoll (density 
1.114 gjml: 8.2% Ficoll) (Neutrophil Isolation Media, Los Alamos 
Diagnostics, Los Alamos, NM) in 15 ml conical polystyrene tubes 
(Costar Data Packaging Corp., Cambridge, MA) and centrifuged at 
25 oc for 30 min at 400 X g. Neutrophils were removed by aspira-
tion and washed twice in 10 ml of RPM!, counted by hemocyto-
meter, and resuspended in RPM! at 20 X 106 cellsjmh This proce-
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dure routinely gave neutrophil preparations containing > 95% 
neutrophils of> 98% viability by trypan blue staining. 
Neutrophil Adherence Assay Sequential 6-,um-thick cryostat 
sections of fresh frozen normal human skin were placed at four 
predesignated sites approximately 1 em apart on sterile gelatin-
coated microscope slides. Sections were allowed to dry briefly at 
room temperature and placed in a humidity tray until used 
(< 30 min). Each section was overlaid with 25.0 ,ul of EBA serum, 
EBA IgG, NHS, or normal human IgG diluted in sterile PBS and 
incubated for 30 min at room temperature in a humidity tray. Fol-
lowing incubation, slides were immersed for 15 min in three 
changes of sterile PBS. Excess PBS was carefully removed and the 
slides were stored at 4oC in a humidity tray until used (<60 min). 
Four wells (8 mm diameter X 2 mm deep; 25 ,ul volume) were cut 
in polymer tape on a second slide, and spaced 1 em apart to corre-
spond to the four tissue sections. Each well was loaded at 4 o C with 
25.0 ,ul of cold RPMI containing 250,000 neutrophils, 12% heat-
inactivated NHS, and indicated concentrations of cytokines, endo-
toxin (E. coli lipopolysaccharide 055:BS; Sigma Chemical Co.), or 
buffer controls with or without cytokine-specific antibodies, con-
trol preimmune serum, or PB (Boehringer Mannheim, FRG). Fol-
lowing the addition of neutrophils and reagents to the wells, tissue 
sections were placed over the wells and the slides inverted to allow 
neutrophils to settle over the sections. Wells were incubated 45 min 
(unless otherwise specified) at 3 7 o C in a humidified air atmosphere. 
Following incubation, tissue sections were washed for 5 min in cold 
PBS to remove nonadherent cells. Sections were briefly dried, de-
hydrated in ethanol, and stained with hematoxylin and eosin 
(H&E) . The optimal number of neutrophils/well was determined 
in preliminary studies in which NA was assayed on sections pre-
treated with 10% ABM-positive serum and subsequently incubated 
with neutrophil suspensions containing 67.0 ngjml rTNF and 
50,000-250,000 neutrophilsjwell. 
Measurement of Neutrophil Adherence and Analysis of Re-
sults Neutrophil adherence to epithelial BMs was measured 
without knowledge of experimental condition by counting the 
number of neutrophils adherent to three randomly selected 1-mm 
segments of BM in each H&E-stained skin section using a light 
microscope equipped with a rotating ocular micrometer. The aver-
age number of neutrophils/mm BM was calculated for each section 
and the results expressed as the mean (± SEM) for quadruplicate 
sections. Each experiment was performed 3-6 times using neutro-
phils from at least two donors. Differences between the means of 
paired assays were statistically analyzed using the Student's t-test. 
RESULTS 
rTNF, rGM-CSF, rTNF-Beta, and riL-l Stimulate NA to 
ABM-Treated Epithelial BMs In initial studies, we examined 
the ability of rTNF and ABM to mediate NA to the BM indepen-
dently of each other and in combination. In those experiments, skin 
sections were pretreated with: (1) 10% ABM-positive EBA sera 
(n = 3; ABM titers, 1 : 40- 1 : 80); (2) 10% ABM-negative EBA sera 
(n = 3); (3) 10% NHS (n = 3); (4) 1.0 mgjml EBA IgG (n = 1; 
ABM titer, 1: 160); or (5) 1.0 mg/ml normal human IgG (n = 1). 
Sections were subsequently incubated with neutrophil suspensions 
with and without 67.0 ng/ml rTNF. The results (Figs 1 and 2) 
showed that NA to the BM of sections pretreated with ABM-posi-
tive sera and subsequently incubated with neutrophil suspensions 
containing rTNF (129 ± 45 neutrophils/mm BM) was signifi-
cantly greater (p < 0.001) than adherence to sections pretreated 
with ABM-positive sera and incubated with neutrophil suspensions 
without rTNF (21 ·± 4 neutrophils/mm BM) or sections pretreated 
with NHS or ABM-negative EBA sera and incubated with neutro-
phil suspensions with rTNF (10 ± 2 and 12 ± 6 neutrophilsjmm 
BM, respectively). Similar results were obtained when comparing 
adherence to sections pretreated with ABM-,ositive IgG or normal 
human IgG in the presence and absence o rTNF (Fig 2). These 
results show that optimal NA to the BM is dependent on both 
ABM-positive sera (or ABM-positive IgG) and rTNF. 
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Figure 1. ABM and rTNF mediate NAto the epithelial 
BM of normal human skin. Sequential sections of nor-
mal human skin were treated with: (A) 10% ABM-posi-
tive EBA serum (ABM titer of undiluted serum= 1: 40) 
followed by fluorescein-conjugated antihuman IgG. 
Note linear pattern oflgG at the epithelial BM; (B) same 
dilution of ABM-positivc EBA serum followed by neu-
trophils and 67.0 ng/ml rTNF as described in Materials • 
and Metlrods. Note neutrophils adherent to the BM 
(arrows}; (C) represents ABM-positive EBA serum fol-
lowed by neutrophils in the absence of rTNF. Note 
relative absence of neutrophils at the epithelial BM 
(magnification X 400). 
In similar experiments, we examined the ability of 0.67 ng/ml 
rGM-CSF, rTNF-beta, riL-l, and riL-3 to mediate NAto sections 
pretreated with 10%: ABM-positive EBA sera (n = 3); ABM-nega-
tive EBA sera (n = 3); or NHS (n = 3) . The results (Table I) showed 
significantly greater (p < 0.01) adherence when sections were pre-
treated with ABM-positive sera and subsequently incubated with 
rGM-CSF, rTNF-beta, or riL-l than when incubated with ABM-
positive sera or cytokines alone. At the cytokine concentrations used 
in these experiments, we observed no stimulation with riL-3 and no 
evidence that any of the cytokines stimulated adherence indepen-
dently of ABM. 
Neutrophil Adherence to ABM-Treated BM Is Cytokine-
Concentration-Dependent In this experiment, we compared 
the ability of rTNF, rGM-CSF, rTNF-beta, riL-l, and riL-3 to 
mediate.concentration-dependent NA. In parallel experiments, skin 
sections were pretreated with 10% ABM-positive EBA serum 
(ABM titer = 1 : 40) and subsequently incubated with neutrophil 
suspensions with and without 0.067-67.0 ng/ml of rTNF, rGM-
CSF, rTNF-beta, or riL-3 and 0.067-6.7 ng/ml of riL-l. We were 
unable to test concentrations of riL- l greater than 6.7 ng/ml be-
cause of the low stock concentration of that cytokine. The results 
(Fig 3) showed that NA was rTNF, rGM-CSF, rTNF-beta, and 
riL-l concentration dependent. Dose-response curves with rTNF 
and rGM-CSF were similar. Both cytokines stimulated NA at con-
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Figure 2. ABM and rTNF mediate NA to the epithelial BM of normal 
human skin. N eutrophil adherence (NEUT /mm BM) was assayed on skin 
sections pretreated with either: 10% normal human serum (NHS, n = 3); 
1 mg/ml normal human IgG (NH!gG, n = 1); 10% ABM-negative EBA 
serum (EBA, ABM-, n = 3); 10% ABM-positive EBA serum (EBA, 
ABM+, n = 3); or 1 mgjml ABM-positive EBA lgG (EBA IgG, n = 1). 
Following treatmen t with sera and IgG fractions, sections were incubated 
with neutrophils in the presence (filled bars) or absence (opetl bars) of 67.0 
ng/ml rTNF. Values are absolute numbers of neutrophils counted. Error 
bars represent SEM of three experiments . 
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centrations < 0.067 ng/ml, and stimulated peak activity at 6. 71 67.0 ng/ml. The doses of rTNF-beta and riL-l required to stimu la~e NA were greater and levels of stimulation less than observe~ 
wtth rTNF and rGM-CSF. As in the previous experiment, we ob, 
served no stimulation with riL-3. 
Stimulation O fNA Is Cytokine-Specific and Not Due to En, 
dotoxin To confirm the specificity of cytokine stimulation an~ 
exclude a role for endotoxin, skin sections were pretreated wit~ 
10% ABM-positive EBA serum (ABM titer, 1: 40) and subsequent!)' 
incubated with neutrophil suspensions containing increasing con, 
centrations (0.067- 67.0 ng/ml) of cytokines alone or cytokine~ 
plus: (1) cytokine-specific antibodies (4.0% by volume); (2) cyto, 
kines plus control normal rabbit serum (4 .0% by volume); or (3) 
cytokines plus 40 ,ug/ml PB. Appropriately diluted cytokines wer~ 
preincubated for 10 min at 25 o C with cytokine-specific antisera 
control preimmune serum, or PB before adding neutrophils. W ~ 
observed (Figs 4 A-D), over a broad range of cytokine concentra1 
tions, that cytokine-specific antisera could inhibit cytokine-stimu, 
lated NA significantly more than control (nonimmune) rabbi~ 
serum and that PB did not inhibit stimulation. 
In other experiments, we compared the ability of rTNF and en, 
dotoxin to stimulate NA on ABM-treated skin sections in th~ 
presence and absence of PB. The results (Fig 5) showed PB coul~ 
completely inhibit stimulation by endotoxin but not rTNF. Fur, 
Table I. Effect of ABM and Cytokines on Neutrophil Adherenc~ 
to Epithelial BM• 
Treatment 
NHS+BUFFER 
NHS + rGM-CSF 
NHS + rTNF-beta 
NHS + riL-1 
NHS + r!L-3 
ABM-N eg. EBA +Buffer 
ABM-Neg. EBA + rGM-CSF 
ABM-Neg. EBA + rTNF-beta 
ABM-Neg. EBA + r!L-1 
ABM-Neg. EBA + riL-3 
ABM-Pos. EBA +Buffer 
ABM-Pos. EBA + rGM-CSF 
ABM-Pos. EBA + rTNF-beta 
ABM-Pos. EBA +riL- l 
ABM-Pos. EBA + r!L-3 
Neutrophil Adherence 
(Neutrophiljmm BM) ± SEM 
2±3 
6±3 
3 ± 1 
2±1 
3±1 
3±1 
5±3 
2±1 
3±2 
3±1 
12 ± 4 
66 ±7 
41 ± 4 
48 ± 6 
13 ± 2 
p' 
< 0.001 
< 0.01 
< 0.01 
• Skin sections were pretreated with either NHS (n = 3), ABM-negative EBA serum 
(ABM-NEG. EDA: n = 3), or ABM-positive EBA serum (ABM-POS. EBA; n = 3), and 
subsequently incubated with neutrophils and either0.67 ng/ml rGM-CSF, rTNF-beta, 
riL-l, r!L-3, or an equivalent volume ofO.Ol% BSA in RPM!. 
1 p values were derived by comparing NA in the presence of ABM-POS. EBA sen 
plus buffer and ABM-POS. EBA sera plus cyrokine. 
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Figure 3. Results of a representative experiment (n = 4) comparing the 
effects of 0.067-67.0 ng/ml cytokines of NA. Skin sections were pretreated 
with 10% ABM-positive EBA serum and subsequently incubated with neu-
trophils in the presence and absence of specified concentrations of cytokines. 
Neutrophil adherence (NEUT /mm BM) was calculated by subtracting ad-
herence to ABM-treated sections in the absence of cytokine from adherence 
in the presence of cytokine. Error bars represent SEM of quadruplicate 
samples. 
thermore, the results showed that approximately 100-1,000 times 
more endotoxin than rTNF was required to stimulate NA, and that 
the highest level of stimulation by endotoxin was only about 50% 
the level of stimulation by rTNF. 
In other studies (results not shown), we found that heat denatura-
tion of cytokines and endotoxin for 10 min at lOOoC caused> 90% 
inhibition of cytokine-stimulated NA but no significant inhibition 
of endotoxin-stimulated NA. 
rTNF-Stimulation of NA Is ABM-Concentration-Depen-
dent To determine the effect of ABM concentration on rTNF-
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Figure 5. Results of a representative experiment (n = 3) examining the 
effect of 40 tLg/ml PB on endotoxin (endotox) and rTNF-mediated NA. 
Skin sections were pretreated with 10% ABM-positive· EBA serum and 
subsequently incubated with neutrophils and 0.067-67.0 tLg/ ml: endotoxin 
alone (diagotzal bars); endotoxin plus PB (cross-hatched bars); or 0.67-67.0 
ng/ml: rTNF alone (opeu bars); or rTNF plus PB (solid bars). Values are 
absolute numbers of neutrophils counted. Error bars, SEM at quadruplicate 
samples. 
stimulated NA, skin sections were pretreated with serial dilutions of 
EBA serum (ABM titer 1 : 40; 1 :5-1 : 320 dilutions) or IgG (ABM 
titer, 1 : 160; 0.125-2.0 mg/ml dilutions), and subsequently incu-
bated with neutrophils in the presence or absence of 67.0 ng/ ml 
rTNF. The results showed an EBA serum (Fig 6A) and an EBA IgG 
(Fig 6B) concentration-dependent increase in rTNF-stimulated 
NA. Stimulation was detectable at an EBA serum titer of 1:40 
(identical to the ABM titer) and increased with increasing serum 
concentration to plateau at a titer of 1: 10. Likewise, stimulation 
increased from 0.125-2.0 mg/ml EBA IgG. In sections pretreated 
with equivalent concentrations ofNHS or normal human IgG, we 
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Figure 4. Results of a representative experiment (n = 3) examining the specificity of cytokine-stimulated adherence. Skin sections were treated with 
ABM-positive serum followed by neutrophils and: cytokines alone (uarrow cross-hatched bars); cytokines plus 40 tLg/ml PB (wide cross-hatched bars); cytokines 
plus control (preimmune) rabbit serum (ope11 bars); or cytokines plus specific rabbit anticytokine antibody (filled bars) . Values are absolute numbers of 
neutrophils counted. Error bars represent SEM of quadruplicate samples. 
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Figure 6. Results of representative experiments (n = 4) in which skin sec-
tions were pretreated with: (A) indicated dilu tions of ABM-positive EBA 
serum (cross-hatched bars) or NHS (open bars); or (B) ABM-positive EBA IgG 
(cross-hatched bars) or normal human IgG (NH lgG) (ope11 bars). All sections 
were subsequently incubated With neutropluls and 67.0 ngfml rTNF. 
Values for NHS plus rTNF and NH lgG plus tTNF are absolute numbers of 
neutrophils counted. Values for (EBA + rTNF}-EBA and (EBA IgG + 
rTNF)-EBA were obtained by subtracting background adherence of neutro-
phils to sections trea ted with EBA serum or EBA IgG in the absence of 
rTNF. Error bars, SEM of quadruplicate samples. 
observed significantly less adherence and a relatively small serum or 
IgG concentration effect. 
rTNF-Stimulated NA Is Due in Part to a Time-Dependent 
Effect of rTNF on the Neutrophil To determine the target of 
rTNF stimulation, neutrophils and ABM-treated sections were pre-
treated with 67.0 ng/ml rTNF or RPMI at 37 oC for 30 min and 
washed to remove residual rTNF pnor to the assay. The results (F1g 
7) showed NA to RPMI-treated skin sec~ions incubated w~th 
rTNF-treated neutrophils (66 ± 5 neutroph1ls/mm B1'·:J-) was stg-
nificantly greater (p < 0.01) than to ~TNF-treated skm ~ecttons 
incubated with RPMI-treated neutrophtls (20 ± 8 neutrophtls/mm 
BM). In other experiments, neutrophils were preincubated with 
67 .0 ng/ml rTNF or buffer for 15 min at 23oC: and washed twice 
before being incubated with ABM-treated secttons. C~lls premcu-
bated with rTNF, but not buffer, adhered to the BM JUSt as effec-
tively as cells simultaneously incubated with ABM-treated sections 
and rTNF (results not shown). . 
To determine the kinetics of rTNF-sttmulated NA, ABM-treated 
skin sections were incubated with neutrophil suspensions contain-
ing 67.0 ng/ml rTNF for 4 -45 mins, and tl~e react~ on stopl?ed at 
intervals by rinsing slides in ice-cold PBS and rmmed1ately fixmg 111 
1 OOo/o ethanol. The results (Fig 8) showed N A was detectable by 9 
min of incubation and peaked at 30-45 min. Forty percent of peak 
NA was detectable by 15 min. Similar results were obtained if neu-
trophils.were pretreated with rTNF for varying times and washed 
prior to incubation with skin sewons (data not shown). 
rTNF-Stimulated NA Is Blocked by Monoclonal Antibodies 
to Neutrophil Fc(gamma)RIII To examine the possibility that 
rTNF-stimulated NA was mediated by neutrophil Fc(gamma)RIII, 
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Figure 7. Results of a representative experiment (n = 3) showing chat rh~ 
adherence stimulating effect of rTNF is mediated, in part, by an effect on th~ 
neutrophil. ABM-treated skin sections (ABM-BM complex) and neutrophi( 
suspensions were separately incubated with bufFer or 67.0 ngfml rTNF fo~ 
30 min at 25 • C. Buffer and rTNF-treated skin sections were then incubate~ 
w1th buffer (opw bars) or rTNF-treated (cross-hate/red bars) neutrophils, 
Values indicate total number of neutrophils counted. Error bars, SEM 0~ 
quadruplicate samples. 
skin sections were pretr~ated with EBA serum and subsequentl)• 
mcubated w1th neutropl)]ls and rTNF in the presence of increasin 
concentration of monoclonal antibody (3G8) to Fc(gamma)RIII o~ 
monoclonal antibodies (HB95 and HB120) to HLA framewor~ 
specificities. Neutrophils were preincubated for 10 min at 23 oC 
with rTNF and monoclonals prior to incubation with skin sections. 
The results (Fig 9) showed that 3G8 caused a dose-dependent inhi, 
bition of rTNF-stimul ated NA. Inhibition by 3G8 (29%) was 
observed a~ a. co~centration of < 1.0 fl.g/ ml and plateaued at 
7 5 -80% mh1b1t1on at a concentration of < 10 fl.g/ml. 
No dose-dependent inhibition was observed with HB120 or HB95 
and inhibition did not exceed 20% at concentrations as high a~ 
1.0 mg/ml. 
DISCUSSION 
Evidence is accumulating that generated cytokines may contribute 
to inflammation and tissue injury in autoantibody and immune-
complex-mediated diseases, although the mechanisms are un-
known. Studies showing that cytokines can stimulate the functional 
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Figure 8. Results of a representative experiment (n = 4) showing rapid 
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rive EBA serum and subsequently incuba ted with neutrophils and either 67.0 
ng/ml rTNF (closed circles) or buffer (ope11 circles). The reaction was stopped 
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Figure 9. Results of a representative experiment (n = 6) showing inhibi-
tion of rTNF stimulated NA by monoclonal antibody to Fc(gamma)RIII. 
Skin sections were pretreated with ABM-positive EBA serum and subse-
quently incubated with neutrophils and 67.0 ngjml rTNF plus the indicated 
concentrations of monoclonal antibody (3G8) to Fc(gamma)RIII (opw cir-
cles) or monoclonal antibodies (HB120 and HB9 5) to HLA framework 
antigens (tria11gles a11d .filled circles). Percent inhibition of NA was calculated 
as follows: [(adherence in the absence of monoclonals - adherence in the 
presence of monoclonals)/adherence in the presence of monoclonals] X 
100%. Error bars, SEM of quadruplicate samples. 
activities ofleukocytes, which are adherent to antibody-coated sur-
faces, suggest enhancing the ability of neutrophils to mediate injury 
to antibody-coated cells and tissues may be one mechanism. In this 
study, we explored the possibility that an additional mechanism 
might involve stimulating adherence of leukocytes to tissues coated 
with autoantibodies or immune complexes. 
In this study, we found that the recombinant cytokines, rTNF, 
rGM-CSF, rTNF-beta, and riL-1 could stimulate adherence of neu-
trophils to the epithelial BM of skin sections treated with IgG ABM. 
Evidence that ABM was required was based on the findings that 
rTNF, rGM-CSF, riL-1, and rTNF-beta stimulated significantly 
more adherence to skin sections treated with EBA sera or IgG con-
taining ABM than sections treated with NHS, normal human IgG, 
or EBA sera without ABM. Furthermore, the level of stimulation by 
rTNF closely paralleled titers of ABM in EBA sera and IgG frac-
tions. Additional evidence was the finding that rTNF stimulation 
could be blocked in a dose-dependent manner by a monoclonal 
antibody (3G8) to the low-affinity neutrophil receptor 
(Fc[gamma]RIII) for substrate-bound IgG Fe [44] . 
Cytokines appeared to be responsible for stimulating adherence, 
since stimulation was cytokine-concentration dependent and could 
be inhibited by 50-100% over a broad range of cytokine concentra-
tions by a brief preincubation with cytokine-specific antibodies. In 
addition, stimulation was selective since it was observed with rTNF, 
rGM-CSF, rTNF-beta, and riL-1 but not with riL-3. Failure of 
riL-3 to stimulate adherence was expected since that cytokine has 
previously been shown not to activate neutrophils (42] . Since re-
combinant proteins are a potential source of endotoxin, and since 
endotoxin is a potent primer and direct stimulator of NA, precau-
tions were taken to eliminate or minimize an endotoxin effect 
[47,48] . Tissues and sera were obtained using sterile methods and 
either used immediately or frozen sterile at -70° C. Buffers, media, 
and other reagents were purchased sterile or prepared and stored 
under sterile conditions. Assay chambers were exhaustively washed 
and heat-dried before use. Reagents as well as stock solutions of 
cytokines were found to contain less than 60 pg/ml endotoxin. 
Since cytokine stocks were diluted by at least a factor of 15, they 
could not have contributed more than 4.0 pg/ml of endotoxin to 
the assay. In control studies, we did not observe stimulation of 
adherence by endotoxin concentrations less than 0.670 ,ugjml. To 
further eliminate an endotoxin effect, we performed experiments in 
the presence of 40 ,ugjml PB, which has previously been shown to 
eliminate endotoxin-mediated neutrophil activation [25 ,38,40] . 
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Our studies showed no differences between cytokine-stimulated 
NA in the presence and absence ofPB. Furthermore, we found that 
incubation of cytokines at 100°C for 10 min, a treatment that 
would not be expected to inactivate endotoxin, was sufficient to 
completely inhibit cytokine-mediated stimulation (results not 
shown) (25,32]. 
Stimulated adherence was found to be cytokine dose-dependent. 
rTNF and rGM-CSF were the most potent, consistently stimulated 
adherence at 0.067 ng/ml (2 -4 X 10-12M), and stimulated peak 
adherence by more than 600% at 6.7-67.0 ng/ml. In some cases, 
they stimulated adherence at 0.0067 ng/ml (results not shown). 
rTNF-beta and riL-l stimulated adherence only at concentrations 
5-10 times greater than rTNF and rGM-CSF; and peak levels of 
stimulation with riL-l were only about 50% of those observed with 
equivalent concentrations of rTNF and rGM-CSF. These studies 
show rTNF and rGM-CSF are more potent than rTNF-beta and 
riL-l in stimulating NA in vitro; however, the possibility that the 
activity of native cytokines may differ from their recombinant ana-
logs makes it difficult to make inferences about their relative po-
tency in vivo. Because of reports that cytokines synergisticall y stim-
ul ate some leukocyte functions, we looked for synergism using all 
possible dual combinations of rTNF, rGM-CSF, rTNF-beta, and 
riL-1 at both high and low cytokine concentrations (27,38,49]. We 
found that all combinations were additive in stimulating adherence 
at ]ow but not high concentrations, although we did not observe 
synergism at any concentration (data not shown). 
Stimulated NAto EM-bound ABM appeared to mainly involve a 
direct effect of rTNF on the neutrophil , because it was not observed 
unless the cells were exposed to rTNF ei ther prior to or during the 
assay. The effect of rTNF was rapid and detectable within 10 min, 
with maximal activity observed within 30-45 min. These kinetics 
are similar to those previously reported for stimulation of neutro-
phil-mediated ADCC and other neutrophil functions by TNF, 
GM-CSF, and TNF-beta (25,32,38,40]. We found that rTNF-
stimulated NA could be inhibited in a dose-dependent manner by a 
monoclonal antibody to Fc(gamma)RIII . We have also found that 
rGM- CSF-stimulated NA is specifically blocked by 3G8 (results not 
shown) . Inhibition by 3G8 appeared to be at least partly due to 
specific Fab binding to Fc(gamma)RIII, since 3G8 was significantly 
more effective in inhibiting ad herence than monoclonal antibodies 
to HLA framework antigens. The apparent requirement for 
Fc(gamma)RIII suggests that rTNF may have stimulated adherence 
by an effect on that receptor. Although it has been reported that 
GM-CSF can increase the affinity of neutrophil IgA receptors, stud-
ies have shown that neither rTNF, rGM-CSF, nor TNF-beta in-
creases the affinity or the number of Fc(gamma) receptors on neu-
trophils (40,42]. 
There is evidence that cytokine-stimulated NA to EM-bound 
ABM may be mediated through an effect on the adherence-promot-
ing receptor, CD1 1 b/CD18. There is evidence that this receptor is 
required for neutrophil adherence to a variety of biological and 
synthetic substrates and is upregu lated by rTNF and rGM-CSF, 
with rapid kinetics si milar to those observed in this study (30-
32,38,40,50-53]. A role for CD 11b/CD18 would help explain the 
apparently greater potency of rTNF relative to riL-1, since it has 
been shown that TNF is significantly more effective than IL-1 in 
stimulating CD11 /CD18 expression on neutrophils (29]. A role 
for CD11b/CD18 is also consistent with a requirement for 
FC(gamma)RIII, since it has been shown that a subpopulation of 
CD 11 b-CD 18 receptors is important in mediating Fc-dependent 
neutrophil functions (54,55]. 
The results of th,is study suggest that TNF, GM-CSF, TNF-beta, 
and IL-1 , individually or in combination, may be involved in stim-
ulating immune adherence of neutrophils to autoantibodies and 
immune complexes bound to or deposited in tissues. In tf1at way, 
they could contribute to autoanribody and immune-complex-me-
diated inflammation by promoting localization and Fc-mediated 
activation of neutrophil s at sites of antibody binding or deposition. 
They could facilitate or amplify the inflammatory effects of other 
biological response modifiers, such as activated complement pro-
170 GAMMON ET AL 
teins, or perhaps initiate immune adherence and activation indepen-
dently of other mediators. The ability to independently initiate 
immune adherence and activation in the absence of complement 
acnvat10n suggests that they may be candidates for mediating Fc-
dependent but complement-independent inflammation, which has 
been reported in experimental animal models of glomerulonephri-
tis (56- 58] . The resu~ts of this and ot~er studies also suggest that 
treatment strategies d1rected at preventmg cytokine production or 
function might be of value in treating autoantibody and immune-
complex-mediated diseases. 
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